Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
BMPR1A Antibody (N-term)
Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS: 5
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC-P, E |
|---|---|
| Primary Accession | P36894 |
| Other Accession | Q78EA7, P36895, NP_004320 |
| Reactivity | Human |
| Predicted | Mouse, Rat |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 60198 Da |
| Antigen Region | 30-60 aa |
| Gene ID | 657 |
|---|---|
| Other Names | Bone morphogenetic protein receptor type-1A, BMP type-1A receptor, BMPR-1A, Activin receptor-like kinase 3, ALK-3, Serine/threonine-protein kinase receptor R5, SKR5, CD292, BMPR1A, ACVRLK3, ALK3 |
| Target/Specificity | This BMPR1A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 30-60 amino acids from the N-terminal region of human BMPR1A. |
| Dilution | WB~~1:1000 IHC-P~~1:50~100 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | BMPR1A Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | BMPR1A |
|---|---|
| Synonyms | ACVRLK3, ALK3 |
| Function | On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for BMP2, BMP4, GDF5 and GDF6. Positively regulates chondrocyte differentiation through GDF5 interaction. Mediates induction of adipogenesis by GDF6. May promote the expression of HAMP, potentially via its interaction with BMP2 (By similarity). |
| Cellular Location | Cell membrane {ECO:0000250|UniProtKB:P36898}; Single-pass type I membrane protein. Cell surface {ECO:0000250|UniProtKB:P36895} |
| Tissue Location | Highly expressed in skeletal muscle. |
Provided below are standard protocols that you may find useful for product applications.
Background
The bone morphogenetic protein (BMP) receptors are a family of transmembrane serine/threonine kinases that include the type I receptors BMPR1A and BMPR1B and the type II receptor BMPR2. These receptors are also closely related to the activin receptors, ACVR1 and ACVR2. The ligands of these receptors are members of the TGF-beta superfamily. TGF-betas and activins transduce their signals through the formation of heteromeric complexes with 2 different types of serine (threonine) kinase receptors: type I receptors of about 50-55 kD and type II receptors of about 70-80 kD. Type II receptors bind ligands in the absence of type I receptors, but they require their respective type I receptors for signaling, whereas type I receptors require their respective type II receptors for ligand binding.
References
Kan, L. et al. Stem Cells. January; 27(1): 150?56(2009). Waite, K.A., et al., Hum. Mol. Genet. 12(6):679-684 (2003). Zhou, X.P., et al., Am. J. Hum. Genet. 69(4):704-711 (2001). Astrom, A.K., et al., Mamm. Genome 10(3):299-302 (1999). ten Dijke, P., et al., Oncogene 8(10):2879-2887 (1993). Ide, H., et al., Cytogenet. Cell Genet. 81 (3-4), 285-286 (1998).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
